Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y(12) receptor antagonist, in patients with chronic coronary syndromes

AIMS: To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y(12) receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS). METHODS AND RESULTS: In this double-blind, randomized study of 345 patients with CCS on background oral anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Storey, Robert F, Gurbel, Paul A, ten Berg, Jurrien, Bernaud, Corine, Dangas, George D, Frenoux, Jean-Marie, Gorog, Diana A, Hmissi, Abdel, Kunadian, Vijay, James, Stefan K, Tanguay, Jean-Francois, Tran, Henry, Trenk, Dietmar, Ufer, Mike, Van der Harst, Pim, Van't Hof, Arnoud W J, Angiolillo, Dominick J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556746/
https://www.ncbi.nlm.nih.gov/pubmed/31994703
http://dx.doi.org/10.1093/eurheartj/ehz807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556746/
https://www.ncbi.nlm.nih.gov/pubmed/31994703
http://dx.doi.org/10.1093/eurheartj/ehz807

Ejemplares similares